

Agenda
South West Clinical Senate Council Meeting
 6th December 2017, 10:00 am – 16.00 pm, Taunton Rugby Football Ground
 Chair: Dr David Halpin

9:30	Arrival – refreshments available		
<i>To what extent and how should the transition to use of biosimilar medicines be prioritised to enable the provision of best value care in the NHS? Does the Clinical Senate support the uptake of biosimilar medicines at pace and how can their best practice use be maximised?</i>			
10.00-10.15	1	Introduction & Senate Business - Principles & Tobacco Prevention - Workforce Senate - Conference March 22 nd 2018 - Biosimilars and South West Data	David Halpin, Chair
10.15-10.45	2	Setting the Scene: Medicines Value Programme and Biosimilar Medicines Commissioning Framework	Stephen Brown, Regional Pharmacist, NHS England South
10.45-11.15	3	The MHRA Regulatory and Licensing Process	Anne Cook, Biologicals Quality Assessor, Licensing Division, MHRA
11.15-11.30	<i>Coffee Break</i>		
11.30-12.00	4	Pharmaceutical Perspective	Keiron Hughes Head of Strategic Pricing, MSD Pharmaceuticals (Merck Sharp & Dohme Limited)
12.00-12.45	5	Case Study 1: Infliximab	Dr Nick Kennedy, Consultant Gastroenterologist, RD&E
12.45-13.00	6	Patient Experience & Survey Findings: what is important to patients when changing medication?	Kevin Dixon, Chair of the South West Citizens' Assembly
13.00-13.45	<i>Lunch provided</i>		
13.45-14.45	7	Group Work	All
14.45-15.45	8	Feedback and Recommendations	Senate Council
15.45-16.00	9	AOB and Close	David Halpin

READING:

1. Biosimilar Guide <https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf>
2. Biologicals Commissioning Framework <https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf>
3. <https://www.nice.org.uk/guidance/ktt15/resources/biosimilar-medicines-58757954414533>
4. Regional Uptake Data (to be tabled)
5. Biosimilars in the EU (attached)

2018 DATES: 1st Feb, 22nd Mar, 17th May, 19th July, 27th Sept, 29th Nov